Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 6;220(12):1885-1891.
doi: 10.1093/infdis/jiz030.

Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma

Joanna Hellmuth  1 , Bonnie M Slike  2   3 , Carlo Sacdalan  4 , John Best  1 , Eugene Kroon  4 , Nittaya Phanuphak  4 , James L K Fletcher  4 , Peeriya Prueksakaew  4 , Linda L Jagodzinski  2 , Victor Valcour  1 , Merlin Robb  2   3 , Jintanat Ananworanich  2   3   4   5 , Isabel E Allen  6 , Shelly J Krebs  2   3 , Serena Spudich  7
Affiliations

Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma

Joanna Hellmuth et al. J Infect Dis. .

Abstract

Background: Chronic immune activation in the blood and central nervous system is a consequence of human immunodeficiency virus (HIV) infection that contributes to disease morbidity and can occur despite virally suppressive antiretroviral therapy (ART). The trajectory of HIV-related inflammation may vary with the timing of ART initiation. We examined immune activation markers in cerebrospinal fluid (CSF) and blood specimens collected over 96 weeks from participants who initiated ART during acute HIV infection (AHI).

Methods: RV254/SEARCH010 study participants with AHI underwent CSF (n = 89) and plasma (n = 146) sampling before initiating ART and at weeks 24 and 96 of treatment. A majority participants (64.4%) received a standard ART regimen (hereafter, "standard ART"), with some (34.7%) also receiving maraviroc and raltegravir for the first 24 weeks (hereafter, "ART plus"). We compared neopterin, CXCL10, CCL2, and interleukin 6 (IL-6) levels in the AHI group to those in 18 healthy, uninfected controls.

Results: Following 24 and 96 weeks of treatment, levels of all CSF markers normalized while levels of several plasma markers remained elevated in the AHI group (P < .001). Participants receiving the ART-plus regimen had lower median plasma CCL2 levels at week 24 and lower plasma neopterin levels at week 96.

Conclusions: ART initiation during AHI differentially impacts the brain compartment, with markers of inflammation returning to normal levels in the CSF, where they were sustained at week 96, but not in plasma.

Keywords: CSF; acute HIV; immune activation; inflammation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Levels of the immune activation markers neopterin (A), CXCL10 (B), CCL2 (C), and interleukin 6 (IL-6; D) in cerebrospinal fluid and plasma in all available samples from participants with acute human immunodeficiency virus (HIV) infection (AHI) before (week 0) and 24 and 96 weeks after antiretroviral therapy initiation, compared with those in HIV-negative healthy controls. Mean values are denoted by central horizontal lines, and standard deviations are denoted by upper and lower horizontal lines.
See this image and copyright information in PMC

Comment in

References

    1. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119:51–83. - PMC - PubMed
    1. Krebs SJ, Slike BM, Sithinamsuwan P, et al. ; SEARCH 011 study team Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. AIDS 2016; 30: 1533–42. - PMC - PubMed
    1. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:168–73. - PMC - PubMed
    1. Edén A, Marcotte TD, Heaton RK, et al. . Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One 2016; 11:e0157160. - PMC - PubMed
    1. Ulfhammer G, Edén A, Mellgren Å, et al. . Persistent CNS immune activation following >10 years of effective HIV antiretroviral treatment. AIDS 2018 Sep 24; 32:2171–8. - PubMed

Publication types

MeSH terms